The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study

The Journal of Hospital Infection
P R P BeharA C Kalil

Abstract

The aim was to evaluate the effect of control selection on risk factor analysis for extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-KP) infections. Four contemporaneous case-control studies were conducted prospectively with 372 patients: Study 1 (ESBL-KP-infected vs non-infected); Study 2 (ESBL-KP-infected vs non-ESBL-KP-infected); Study 3 (all KP-infected vs non-infected); Study 4 (non-ESBL-KP-infected vs non-infected). Time at risk (TAR, i.e. duration of hospital stay) was the most significant risk factor [Study 1: odds ratio (OR): 5.74 (95% CI: 2.26-14.59; P<0.001); Study 2: 3.52 (1.47-8.43; P=0.005); Study 3: 2.68 (1.57-4.58; P<0.001)]; central venous catheterisation (CVC) was a risk factor in Study 1: 5.31 (1.67-16.82; P=0.005) and Study 3: 2.10 (1.04-4.27; P=0.04). Prior use of cephalosporins (PUC) was a risk factor only in studies with non-infected patients as controls [Study 1: 5.64 (1.90-16.72; P=0.002) and Study 3: 4.60 (2.09-10.13; P<0.001)]. The ORs were uniformly lower with 'non-ESBL-KP-infected' (TAR: 3.52; CVC: 2.07; PUC: 1.97) compared with 'non-infected' patients (TAR: 5.74; CVC: 5.31; PUC: 5.64) as control groups. Selection of control patients has a crucial role in the evaluation of risk...Continue Reading

References

Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L PirothM Vincent-Martin
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G A Jacoby
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A AsensioR Cantón
Mar 18, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D L PatersonV L Yu
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·K S KayeY Carmeli
Nov 30, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J A RebuckM E Rupp
Mar 27, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A D HarrisM H Samore
Apr 3, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E LautenbachN O Fishman
May 25, 2002·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Gregory BissonEbbing Lautenbach
May 29, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anthony D HarrisYehuda Carmeli
May 29, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L Paterson
May 4, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Anthony D HarrisEli Perencevich
May 4, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Keith S KayeYehuda Carmeli

❮ Previous
Next ❯

Citations

Jun 10, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Petros I RafailidisMatthew E Falagas
Apr 22, 2015·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Mirian Cristina OliveiraVandack Alencar Nobre
Oct 14, 2008·Expert Review of Anti-infective Therapy·Jesús Rodríguez-Baño, Alvaro Pascual
Jul 24, 2020·PloS One·Szabolcs Szekér, Ágnes Vathy-Fogarassy
Sep 16, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P CassierP Chavanet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Cheol-In KangKang-Won Choe
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Anucha ApisarnthanarakLinda M Mundy
Journal of Infection in Developing Countries
Kutbettin Demirdag, Salih Hosoglu
© 2021 Meta ULC. All rights reserved